首页> 外文OA文献 >The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series

【2h】

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series

机译：向Brentuximab Vedotin添加苯麦蛋白导致儿童，青少年和年轻成年人的完全代谢缓解率提高，具有复发和难治性古典霍奇金淋巴瘤：回顾性单中心系列

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Annabel McMillan; Aideen T. ONeill; William Townsend; Jonathan. Lambert; Andres Virchis; Raakhee Shah; Leon Menezes; Paul Humphries; Kirsten Von Both; Victoria Grandage; Ben Carpenter; Rachael Hough; Kirit M. Ardeshna; Stephen Daw;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series [J] . McMillan Annabel, ONeill Aideen T., Townsend William, British Journal of Haematology . 2021,第3期

机译：向Brentuximab Vedotin添加Bendamustine导致儿童，青少年和年轻成人的完全代谢缓解率提高，具有复发和难治性古典霍奇金淋巴瘤：回顾性单中心系列
2. Brentuximab vedotin plus bendamustine in relapsed and refractory classical Hodgkin lymphoma in children, adolescents and young adults: a single centre experience [J] . McMillan A., ONeill A. T., Humphries P., Klinische Paediatrie . 2020,第2期

机译：Brentuximab Vedotin Plus Bendamustine在儿童，青少年和年轻人中复发和难治古典霍奇金淋巴瘤：单一中心经验
3. Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma [J] . Harker-Murray Paul, Leblanc Thierry, Mascarin Maurizio, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用Nivolumab和Brentuximab Vedotin（BV）的反应适应治疗，其次是BV和Bendamustine用于次优应答，儿童，青少年和具有标准风险复发/难治经典霍奇金淋巴瘤的年轻成年人
4. Brentuximab vedotin with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma: A Children’s Oncology Group Single-arm Phase 1 / 2 Trial. [O] . Professor Peter D. Cole, Professor Kathleen M. McCarten, Qinglin Pei, -1

机译：布伦妥昔单抗维多汀联合吉西他滨用于小儿和年轻成人复发性或难治性霍奇金淋巴瘤的儿童：儿童肿瘤学组单臂1/2期试验。
5. Relabáló/refrakter Hodgkin-lymphoma brentuximab vedotin\ud kezelése. Hazai tapasztalatok | Brentuximab vedotin treatment in patients with relapsed or refractory \ud Hodgkin lymphoma. \ud A Hungarian retrospective study [O] . Molnár, Zsuzsa, Pinczés, László Imre, Piukovics, Klára, 2017

机译：复发性/难治性霍奇金淋巴瘤brentuximab vedotin \ ud 他的治疗。国内经验布伦特昔单抗用于复发或难治性患者霍奇金淋巴瘤。 \ ud 匈牙利回顾性研究

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series

著录项

相似文献

相关主题

期刊订阅